Blog
RSS FeedPosted by Michael Wonder on 09 Jul 2017
Why Obamacare’s loudest critics aren’t as loud anymore
8 July 2017 - Members of Congress returning home for the July 4 recess last week were met with rallies, ...
Posted by Michael Wonder on 09 Jul 2017
The private equity firm that quietly profits on top selling drugs
8 July 2017 - Cashing in on rising drug prices often unleashes an outcry from consumers and politicians. ...
Posted by Michael Wonder on 08 Jul 2017
Drug trade group sues Maryland over first-in-the-nation price-gouging law
6 July 2017 - A generic-drug trade group is suing Maryland over a price-gouging law that is set to go ...
Posted by Michael Wonder on 08 Jul 2017
Endo gives in to FDA demand and agrees to yank its opioid painkiller
7 July 2017 - In the end, the executive team at Endo International blinked. ...
Posted by Michael Wonder on 08 Jul 2017
FDA approves new treatment for sickle cell disease
7 July 2017 - The U.S. FDA today approved Endari (L-glutamine oral powder) for patients age five years and older ...
Posted by Michael Wonder on 07 Jul 2017
Rare disease drug makers join in worries over GOP health overhaul
7 July 2017 - A threat to drugs that brought in $114 billion last year. ...
Posted by Michael Wonder on 06 Jul 2017
White House backs conservative health plan, but G.O.P. leaders are leery
6 July 2017 - The White House is backing a health care proposal that would make it easier for insurance ...
Posted by Michael Wonder on 06 Jul 2017
How the GOP and Democrats might begin to compromise on health care
5 July 2017 - Washington — Senate Majority Leader Mitch McConnell warned last week that Republicans’ failure to pass comprehensive ...
Posted by Michael Wonder on 06 Jul 2017
Bristol-Myers Squibb’s Orencia (abatacept) receives FDA approval for treatment of active psoriatic arthritis in adults
6 July 2017 - Orencia demonstrated symptom improvement in two randomised, double-blind, placebo-controlled trials that included adult patients with psoriatic arthritis ...
Posted by Michael Wonder on 06 Jul 2017
Vertex raises price of top-selling cystic fibrosis drug for first time
5 July 2017 - Vertex Pharmaceuticals has raised the price of its best-selling cystic fibrosis drug for the first time, ...
Posted by Michael Wonder on 05 Jul 2017
Patient reported outcomes — are they living up to their potential?
5 July 2017 - There is a growing chorus of support for measuring patient-reported outcomes in clinical care. ...
Posted by Michael Wonder on 05 Jul 2017
Cardiome' partner SteadyMed submits U.S. new drug application for Trevyent for the treatment of pulmonary arterial hypertension
3 July 2017 - Cardiome Pharma Corporation today announced that partner SteadyMed submitted a new drug application to the U.S. FDA ...
Posted by Michael Wonder on 04 Jul 2017
Generic drug prices rise when market competition drops
3 July 2017 - Generic drug price increases are strongly linked to market competition, according to data published online July ...
Posted by Michael Wonder on 04 Jul 2017
Are drug regulators really too slow?
29 June 2017 - Regulators are often accused of delaying approval of new drugs by slow processes. Tom Marciniak and ...
Posted by Michael Wonder on 04 Jul 2017
Amphora (L-lactic acid, citric acid, and potassium bitartrate) receives QIDP designation from the FDA
29 June 2017 - Designation includes two separate indications and provides eligibility for priority review and additional exclusivity. ...